Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial.

Chestnut Hill Hospital, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.
Annals of internal medicine (Impact Factor: 16.1). 07/2009; 150(12):830-9, W147-9.
Source: PubMed

ABSTRACT Red yeast rice is an herbal supplement that decreases low-density lipoprotein (LDL) cholesterol level.
To evaluate the effectiveness and tolerability of red yeast rice and therapeutic lifestyle change to treat dyslipidemia in patients who cannot tolerate statin therapy.
Randomized, controlled trial.
Community-based cardiology practice.
62 patients with dyslipidemia and history of discontinuation of statin therapy due to myalgias.
Patients were assigned by random allocation software to receive red yeast rice, 1800 mg (31 patients), or placebo (31 patients) twice daily for 24 weeks. All patients were concomitantly enrolled in a 12-week therapeutic lifestyle change program.
Primary outcome was LDL cholesterol level, measured at baseline, week 12, and week 24. Secondary outcomes included total cholesterol, high-density lipoprotein (HDL) cholesterol, triglyceride, liver enzyme, and creatinine phosphokinase (CPK) levels; weight; and Brief Pain Inventory score.
In the red yeast rice group, LDL cholesterol decreased by 1.11 mmol/L (43 mg/dL) from baseline at week 12 and by 0.90 mmol/L (35 mg/dL) at week 24. In the placebo group, LDL cholesterol decreased by 0.28 mmol/L (11 mg/dL) at week 12 and by 0.39 mmol/L (15 mg/dL) at week 24. Low-density lipoprotein cholesterol level was significantly lower in the red yeast rice group than in the placebo group at both weeks 12 (P < 0.001) and 24 (P = 0.011). Significant treatment effects were also observed for total cholesterol level at weeks 12 (P < 0.001) and 24 (P = 0.016). Levels of HDL cholesterol, triglyceride, liver enzyme, or CPK; weight loss; and pain severity scores did not significantly differ between groups at either week 12 or week 24.
The study was small, was single-site, was of short duration, and focused on laboratory measures.
Red yeast rice and therapeutic lifestyle change decrease LDL cholesterol level without increasing CPK or pain levels and may be a treatment option for dyslipidemic patients who cannot tolerate statin therapy.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Red yeast rice (i.e., rice fermented with Monascus spp.) is currently sold via the Internet as a dietary supplement. Claims state that red yeast rice has the ability to lower blood cholesterol concentrations. The mechanism of action is well characterised because the red yeast rice constituent monacolin K is identical with lovastatin, an inhibitor of the hydroxymethylglutaryl-CoA (HMG-CoA) reductase that is used in many cholesterol-lowering medicinal products. The aim of this article is to evaluate the properties of red yeast rice products that are marketed via the Internet. Three out of five analyzed products may reach the daily dosage of 10 mg lovastatin, which is necessary for the substantiation of health claims on the maintenance of normal blood LDL-cholesterol levels as suggested by the Scientific Opinion of the European Food Safety Authority. 10 mg is also the starting dosage of medicinal lovastatin products on the German market. From a regulatory standpoint, red yeast rice products would rather have to be sold as medicinal products than as food supplements as they clearly exhibit a pharmacological action that is comparable to approved statin-containing medicinal products. This also implies potential adverse effects and interactions, about which the consumer is insufficiently informed in the case of food supplements. The lack of control over the Internet market is evidenced by the fact that four of the tested products were not marketable in conventional trade in Germany due to violations of labelling rules.
    Deutsche Lebensmittel-Rundschau: Zeitschrift für Lebensmittelkunde und Lebensmittelrecht 07/2012; 108(7):357-360. · 0.06 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Metabolic syndrome (MetS) comprises a spectrum of clinical phenotypes in which dyslipidemia, dysglycemia and hypertension are clustered and where all share a high level of oxidative stress and an increased risk of cardiovascular disease. This study examines the effect of a nutritional supplement combining red yeast rice and olive fruit extract on the lipid profile and on oxidative stress in a population of patients with MetS. In a double blind placebo controlled randomized trial, 50 persons with MetS, as defined by the ATPIII criteria, received the study product or placebo for 8 weeks. The study product contained 10.82 mg of monacolins and 9,32 mg of hydroxytyrosol per capsule, and is commercialized as Cholesfytol plus. The primary outcome measure was the difference in LDL reduction between intervention and control groups. Furthermore, differences in changes of CH, HDL, ApoA1, ApoB, HbA1c and oxLDL were measured, as well as side-effects, CK elevation, changes in clinical parameters and in cardiovascular risk. In the intervention group, LDL cholesterol was lowered by 24% whereas it increased by 1% in the control group (p < 0.001). Other effects observed were a change in total cholesterol (-17% in the intervention group vs +2% in the control group, p < 0.001), apolipoprotein B (-15% vs +6%, p < 0.001), and TG (-9% vs + 16%, p = 0.02). Oxidized LDL decreased by 20% vs an increase of 5% in the control group (p < 0.001). Systolic and diastolic arterial blood pressure decreased significantly by 10 mmHg (vs 0% in the control group, p = 0.001) and 7 mmHg (vs 0% in the control group, p = 0.05) respectively. One person in the intervention group, who suffered from Segawa's syndrome, dropped out because of severe muscle ache. The combination of active products in this study may be an alternative approach to statins in people who do not need, or cannot or do not want to be treated with chemical statins. Side effects, effects on oxidative stress and on glucose metabolism need to be examined more thoroughly. NCT02065180 (February 2014).
    BMC Complementary and Alternative Medicine 12/2015; 15(1):576. DOI:10.1186/s12906-015-0576-9 · 1.88 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Red mould rice is presently offered under various trade names primarily through the internet, mainly as a food supplement with a cholesterol-lowering effect, i.e. without legal approval as a drug. This development caused the DFG Senate Commission on Food Safety to evaluate red mould rice with respect to its effects on human health in a first opinion in 2004. The European Food Safety Authority published an assessment of the health claims regarding monacolin K from red mould rice. The SKLM updated its opinion on December 18th 2012. The English version was agreed on November 13th/14th 2013.


Available from